EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 161 filers reported holding EAGLE PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $432,927 | -0.3% | 15,260 | +2.7% | 0.01% | 0.0% |
| Q4 2022 | $434,359 | +11.1% | 14,860 | +0.7% | 0.01% | 0.0% |
| Q3 2022 | $391,000 | -37.6% | 14,756 | +4.6% | 0.01% | -27.3% |
| Q2 2022 | $627,000 | -9.7% | 14,105 | +0.7% | 0.01% | +10.0% |
| Q1 2022 | $694,000 | -1.8% | 14,005 | +1.1% | 0.01% | +11.1% |
| Q4 2021 | $707,000 | -8.5% | 13,855 | 0.0% | 0.01% | -10.0% |
| Q3 2021 | $773,000 | +215.5% | 13,855 | +142.9% | 0.01% | +233.3% |
| Q2 2021 | $245,000 | +2.1% | 5,705 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $240,000 | -13.0% | 5,705 | -3.4% | 0.00% | 0.0% |
| Q4 2020 | $276,000 | -79.9% | 5,905 | -81.7% | 0.00% | -81.2% |
| Q3 2020 | $1,373,000 | -51.3% | 32,305 | -45.1% | 0.02% | -51.5% |
| Q2 2020 | $2,822,000 | +10.1% | 58,804 | +5.6% | 0.03% | -2.9% |
| Q1 2020 | $2,563,000 | +19.0% | 55,704 | +55.6% | 0.03% | +54.5% |
| Q4 2019 | $2,153,000 | +741.0% | 35,804 | +695.6% | 0.02% | +633.3% |
| Q3 2019 | $256,000 | – | 4,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tri Locum Partners LP | 94,922 | $4,063,000 | 1.33% |
| Smith, Graham & Co., Investment Advisors, LP | 277,572 | $11,880,000 | 1.05% |
| Krensavage Asset Management, LLC | 70,804 | $3,030,000 | 1.03% |
| BRANDES INVESTMENT PARTNERS, LP | 716,873 | $30,682,000 | 0.68% |
| GLOBEFLEX CAPITAL L P | 42,357 | $1,813,000 | 0.33% |
| Zebra Capital Management LLC | 6,472 | $277,000 | 0.32% |
| Capital Impact Advisors, LLC | 19,276 | $825,000 | 0.27% |
| Hein Park Capital Management LP | 31,977 | $1,369,000 | 0.26% |
| CHARTWELL INVESTMENT PARTNERS, LLC | 195,340 | $8,361,000 | 0.25% |
| Stanley-Laman Group, Ltd. | 24,000 | $1,027,000 | 0.15% |